DNA vaccines against tumor growth and methods of use thereof
A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a polynucleotide construct operably encoding an a Fra-1 protein, such as a polyubiquitinated human Fra-1 protein, and IL-18, such as human IL-18, in a pharmaceutically acceptable carrier. In a preferred embodiment, the polynucleotide construct is operably incorporated in an attenuated bacterial vector, such as an attenuated Salmonella typhimurium , particularly a doubly attenuated aroA − dam − S. typhimurium . Transformed host cells, methods of inhibiting tumor growth, of vaccinating a patient against cancer, and of delivering genetic material to a mammalian cell in vivo are also described.
1. A DNA vaccine suitable for eliciting an immune response against cancer cells that overexpress Fra-1, the vaccine comprising a polynucleotide construct operably encoding a Fra-1 protein and IL-18 in a pharmaceutically acceptable carrier.
2. The DNA vaccine of claim 1 wherein the polynucleotide construct is operably incorporated in a vector.
3. The DNA vaccine of claim 2 wherein the vector is an attenuated bacterial vector.
4. The DNA vaccine of claim 3 wherein the attenuated bacterial vector is selected from the group consisting of attenuated Salmonella typhimurium, Salmonella typhi, Shigella, Bacillus, Lactobacillus , BCG, Escherichia coli, Vibrio cholerae , and Campylobacter.
5. The DNA vaccine of claim 1 wherein the polynucleotide construct encodes a Fra-1 protein having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 and SEQ ID NO: 4.
6. The DNA vaccine of claim 1 wherein the polynucleotide construct encodes IL-18 having an amino acid sequence selected from the group consisting of SEQ ID NO: 6 and SEQ ID NO: 8.
7. The DNA vaccine of claim 1 wherein the polynucleotide construct comprises a polynucleotide encoding a human or murine Fra-1 protein, and having a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 3.
8. The DNA vaccine of claim 1 wherein the polynucleotide construct comprises a polynucleotide encoding a human or murine IL-18, and having a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5 and SEQ ID NO: 7.
9. The DNA vaccine of claim 1 wherein the polynucleotide construct further encodes IL-12.
10. The DNA vaccine of claim 1 wherein the polynucleotide construct comprises an Fra-1 polynucleotide having a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, and SEQ ID NO: 3 and an IL-18 polynucleotide having a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, and SEQ ID NO: 7.
11. A method of inhibiting tumor growth in a mammal having a Fra-1 overexpressing tumor and comprising the step of administering to the mammal an effective immunological response eliciting amount of a DNA vaccine comprising a polynucleotide construct operably encoding a Fra-1 protein and IL-18 in a pharmaceutically acceptable carrier, whereby the mammal exhibits an immune response elicited by vaccine and specific to tumor cells.
12. The method of claim 11 wherein the polynucleotide construct encodes IL-18 having an amino acid sequence selected from the group consisting of SEQ ID NO: 6 and SEQ ID NO: 8.
13. The method of claim 11 wherein the polynucleotide construct comprises a polynucleotide encoding a human or murine IL-18, and having a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5 and SEQ ID NO: 7.
14. The method of claim 11 wherein the mammal is a human.
15. The method of claim 11 wherein the polynucleotide construct is operably incorporated in an attenuated bacterial vector.
16. The method of claim 15 wherein the attenuated bacterial vector is selected from attenuated Salmonella typhimurium, Salmonella typhi, Shigella, Bacillus, Lactobacillus , BCG, Escherichia coli, Vibrio cholerae , and Campylobacter.
17. The method of claim 15 wherein the vaccine is administered orally.
18. An isolated transformed host cell transfected with a polynucleotide construct operably encoding a Fra-1 protein and IL-18.
19. A method of vaccinating a mammal against a Fra-1 overexpressing cancer, the method comprising the step of administering to the mammal an effective immunological response eliciting amount of a DNA vaccine comprising a polynucleotide construct operably encoding a Fra-1 protein and IL-18 in a pharmaceutically acceptable carrier.
20. The method of claim 19 wherein the vaccine is administered orally.
21. A method of delivery of genetic material to a mammalian cell in vivo comprising orally administering to a mammal a polynucleotide construct operably encoding a therapeutically useful gene product comprising a Fra-1 protein and IL-18.